ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
The Emerging Parkinson's Disease Oxylipin-Ome.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Parkinson Disease (PD) is increasingly considered a proteinopathy and lipidopathy. This proteinopathy+lipidopathy paradigm has been further refined to a fatty acid (FA)-opathy, centering dysregulated FA metabolism as fundamental in PD lipid dysfunction. FA dysfunction can disrupt alpha-synuclein (αS)-membrane interactions, altering αS localization, conformation, and aggregation. Correcting FA dyshomeostasis rescues PD-associated αS phenotypes and is a promising strategy for disease-modifying therapeutics. Herein, we consider the impact of PD FA dyshomeostasis in modifying the bioactive oxylipin-ome. Oxylipin metabolism is complex, and the role of oxylipins in PD is not yet fully determined. This perspective considers PD-associated differences oxylipin profiles, oxylipin precursor polyunsaturated fatty acids (PUFAs), and oxylipin biosynthetic enzymes in human PD studies to explore a potential PD oxylipin-ome signature. Founded on disrupted oxylipin and oxylipin precursor PUFA abundance, higher PUFA intake reducing PD risk and progression, and the association between cyclooxygenase (COX) inhibition and lower PD incidence, we posit that the oxylipin-ome plays a role in PD. Oxylipin metabolism may be a novel target for PD biomarkers and disease-modifying therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.